Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.
about
Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions.Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGNEscape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.Characterization of HIV-1-specific antibodies and HIV-1-crossreactive antibodies to platelets in HIV-1-infected haemophiliac patients.Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2.Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activityInduction of anti-HIV neutralizing antibodies by synthetic peptides.Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots.Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies.Sentinel hospital surveillance of HIV infection in Quebec. Quebec Sentinel Hospital HIV-Seroprevalence Study Group.The natural history of human T lymphotropic virus-III infection: the cause of AIDS.Seroepidemiology of human immunodeficiency virus in Africa.Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimerThe B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.Humoral immune responses to T cell tropic retrovirus simian T lymphotropic virus type III in monkeys with experimentally induced acquired immune deficiency-like syndromeRisk factors for HIV seropositivity among people consulting for HIV antibody testing: a pilot surveillance study in Quebec.Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.Characteristics and clinical significance of a stabilization assay to detect specific antibodies to reverse transcriptase of human immunodeficiency virus.Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen.Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progressionHuman immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation.Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients.Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus.Characterization of Humoral Immune Responses against Capsid Protein p24 and Transmembrane Glycoprotein gp41 of Human Immunodeficiency Virus Type 1 in China.Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infectionDetection of human immunodeficiency virus type 1 (HIV-1) antibody by western blotting and HIV-1 DNA by PCR in patients with AIDS.Practical diagnostic testing for human immunodeficiency virus.Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoproteinPosttranslational modifications distinguish the envelope glycoprotein of the immunodeficiency disease-inducing feline leukemia virus retrovirusExpression of the human immunodeficiency virus envelope glycoprotein is restricted to basolateral surfaces of polarized epithelial cells.Linear B-cell epitopes of the major core protein of human immunodeficiency virus types 1 and 2.Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.Intracellular interaction of human immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membraneDemonstration of two distinct cytopathic effects with syncytium formation-defective human immunodeficiency virus type 1 mutantsPersistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
P2860
Q30356755-FF3647D0-C26E-4766-873C-0B9ECB522079Q33321821-E8EAB5DE-75E8-4EF1-AB05-E8651A789F38Q33504599-A4D35387-2988-48AD-9716-8ABEF14BE3D0Q33504907-31360098-5199-4167-AAB9-15192D737EB5Q33686306-E3DF8D67-BFDD-4EC1-8D08-646441AB4449Q33807129-461DF812-4C05-4247-8C93-B59635F37317Q33826951-A15E879D-183F-4D4F-B90D-0D2684DBDAAAQ33880796-8CE93482-5CBC-4CF5-AC6C-272A5A39120FQ34042316-D56897F4-3DD8-4791-A9CC-C6A8C6C344D4Q34097739-6E24EA9E-A243-4264-902A-F8A70CE1EC68Q34277576-E052488D-2598-4CC1-A35B-69DD34B0D522Q34282439-9212F9E7-E1E0-4A50-AD03-49E36F2CA181Q34288918-56BD8C68-6A47-48CF-AAB7-5D47972F1F71Q34292319-1694D994-FF91-4546-A5FC-95F253F5E95CQ34485260-1393D3D9-1E69-4794-8C3A-D4C8B761E938Q34545986-65B006AD-F7E6-4DB6-9E20-C92BBCA0D3A7Q34578164-325F8406-EDD1-4053-879E-77AB98CF0E76Q34628114-62B1CB3C-8B83-4FD1-A528-E7B2D8E75AB6Q34885869-E68A9D75-0FDB-4DF0-AD05-F4E160C4813DQ35113855-ED0BA6F4-7E50-4DBC-893A-9228F1F449A5Q35224896-99319163-650B-45D0-BDFB-15F010D840E6Q35551617-26256AD7-703D-40A9-909E-9409C94726D1Q35576665-1B0956AE-A081-4528-A386-A4345B9A6854Q35597873-FD9934D2-C08E-4ACC-BF0B-8879820AB4E4Q35597880-513E469F-A59F-4571-8496-8C2F91B0E94FQ35616284-321A1F2B-FA86-44D9-85F1-DA63427AC221Q36179451-1A7D4612-623E-4D6D-A19C-99F7FFA1A4F1Q36423897-4C392810-8512-4BB2-B650-38DB91CACD3AQ36575208-F340C9FB-C49F-486D-AD90-050B4BEE45A6Q36632724-57DEBCCE-4985-4A2F-9D8D-13BDDBA47D1EQ36648889-3BB6F35E-34B2-4896-A189-B5AC5295FF89Q36780124-F77541FF-2B46-4634-8571-39317AFCD720Q36781151-2076A93E-0D62-4A05-919A-5133DF21EFE2Q36782827-7B831CAA-6ACA-4865-963F-AF1D5D1324BCQ36796061-DA99ADFC-CECF-4893-BD00-E1C55CFB08D5Q36796364-43396BB1-1BFF-4DCD-9DE4-379D24DBB485Q36821576-342CA7B3-155A-4B6A-B437-02DFAC329F1FQ36919244-9DB9B551-FAED-441F-801C-5176873BD533Q36949880-D4E4E2D8-F6DA-429D-8567-F7785F81F3A7Q37010852-F65CBE78-E90F-4F74-AABC-D935D579D90F
P2860
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Virus envelope protein of HTLV ...... r antibodies in AIDS patients.
@en
Virus envelope protein of HTLV ...... r antibodies in AIDS patients.
@nl
type
label
Virus envelope protein of HTLV ...... r antibodies in AIDS patients.
@en
Virus envelope protein of HTLV ...... r antibodies in AIDS patients.
@nl
prefLabel
Virus envelope protein of HTLV ...... r antibodies in AIDS patients.
@en
Virus envelope protein of HTLV ...... r antibodies in AIDS patients.
@nl
P2093
P921
P356
P1433
P1476
Virus envelope protein of HTLV ...... r antibodies in AIDS patients.
@en
P2093
P304
P356
10.1126/SCIENCE.2986291
P407
P577
1985-05-01T00:00:00Z